LTR Pharma (ASX:LTP) has announced its nasal spray ‘viagra drug’ SPONTAN has been prescribed by a Brisbane-based men’s health expert under the drug regulator’s Special Access Scheme (SAS). The company listed in the dying days of 2023, and it’s had an interesting debut year on the ASX. In June it saw its shares jump 58%; 1Y gains currently sit above +300%. In a way, LTR Pharma is kind of like the Droneshield of the Healthcare sector right now (ignoring that latter stocks’ recent price action.) The stock has garnered interest from the retail end of the investing ecosystem, but also from fund man…